Executive Summary
Edwards Lifesciences posted Q2 sales up 12.5% year-over-year with raised full-year guidance driven by TAVR and TMTT franchises. The clinical evidence released alongside that growth interrogates selection, not devices. A 2528-patient international M-TEER registry confirms that preprocedural NYHA IV independently predicts 2-year mortality (HR 1.75) even after effective MR reduction, and an infective endocarditis review of TAVR and M-TEER devices confirms that we still lack standardized management for a complication with rising absolute numbers. The market rewarded volume; the literature interrogated selection. That gap is where the case for earlier referral and disciplined patient triage tightens.
- NYHA IV at time of M-TEER for primary MR carries a 31.8% vs 21.1% 2-year mortality despite comparable procedural success — waiting until class IV is too late (Structural Heart).
- Venus Medtech completed enrollment in its self-expanding TAVR pivotal trial, adding another platform to a crowded self-expanding field (MassDevice).
- A radiology-led review of preprocedural CT for redo TAVR crystallizes the growing TAV-in-TAV planning burden as younger patients outlive their index THVs (Radiology: Cardiothoracic Imaging).
- GLP-1 RA add-on therapy was associated with broad post-cardiac-surgery mortality reduction; SGLT2i benefit was confined to HF/CKD subgroups with a renal signal at 600 days in unselected patients (Cardiology in Review).
- A critical appraisal of a recent SAVR survival prediction model flags omission of frailty and lack of external validation — lifetime-management decisions still lack rigorous risk tools (GTCS).
What to watch: Boston Scientific Q2 earnings on July 29 — TriClip trajectory and any commentary on ACURATE neo2 following its US commercial pause will move the tricuspid and self-expanding TAVR narratives.
Aortic Valve (TAVR/TAVI)
Edwards' 13.6% Q2 TAVR sales growth and Venus Medtech's completed self-expanding pivotal enrollment reflect a market expanding faster than durability data can validate. Three technique-focused papers signal where operators are spending their cognitive load: a Radiology: Cardiothoracic Imaging review on preprocedural CT for redo TAVR, a European Cardiology review of BASILICA, and a Future Cardiology review of direct TAVI vs predilatation. All three are downstream consequences of the ESC 2025 lifetime-management mandate: coronary access, valve-in-valve feasibility, and commissural alignment must be planned at the index procedure.
ESC 2025 still recommends SAVR for patients under 70 with low surgical risk (Class I); ACC/AHA 2020 holds the line at under 65. A critical appraisal in GTCS notes that current SAVR survival prediction tools lack frailty variables and external validation — so lifetime-management decisions are being made without adequate risk stratification on either side of the ledger. The direct-TAVI review supports selective, anatomy-driven predilatation over routine BAV, particularly for bicuspid anatomy, severe calcification, or horizontal aorta. A separate JACC Case Reports case of post-valve-in-valve hemoptysis rescued by bronchoscopic cryoextraction is a reminder that complications from redo transcatheter work are entering new territory.
Mitral Valve (MitraClip, PASCAL, TMVR)
[NOTABLE] Waiting until NYHA IV to refer primary MR patients for M-TEER erases much of the intervention's mortality benefit. In a 2528-patient international registry across 27 sites (2009–2023), Structural Heart reports that NYHA IV patients had comparable procedural success (residual MR ≤1+ in 66.7% vs 64.6%) and rehospitalization rates, but 2-year all-cause mortality of 31.8% versus 21.1% (HR 1.75, 95% CI 1.32–2.31, p<0.001). Registry data, not randomized; wide temporal span across device generations — those limitations acknowledged, the signal is consistent with two decades of surgical PMR literature: advanced symptoms and end-organ decompensation predict outcomes independent of what you do to the valve.
ESC 2025 upgraded early MV repair in asymptomatic severe PMR with preserved LV to Class I when 3 or more risk factors are present (AF, SPAP >50 mmHg, LA dilation, ≥moderate TR); ACC/AHA 2020 holds at Class IIa. This registry cuts in favor of the ESC position: by NYHA IV, transcatheter rescue underperforms. TEER remains Class IIa for PMR at high surgical risk in both guidelines — this registry doesn't change that indication, but it argues for earlier referral, whether the destination is surgery or TEER.
Tricuspid Valve (TriClip, TTVR)
No new tricuspid clinical data today. The ESC 2025 Class IIa endorsement of transcatheter TV treatment reframes how Edwards' TMTT revenue growth should be read: US reimbursement expansion will follow, and the TRISCEND II 30-day mortality of 3.1% in the STS/ACC TVT Registry sets the real-world bar. ESC 2025 simultaneously upgraded TV surgery for symptomatic severe primary TR to Class I — up from ACC/AHA 2020's IIa. No head-to-head data exists comparing repair versus replacement or surgical versus transcatheter approaches, and isolated TV surgery outcomes remain heavily contingent on timing of referral.
Surgical vs. Transcatheter Comparisons
No direct head-to-head trials today. A critical appraisal in General Thoracic and Cardiovascular Surgery targets a recent SAVR survival prediction model for lacking frailty variables, external validation, and decision curve analysis — a methodological critique that applies equally to most TAVR risk tools in current use. Lifetime-management decisions are being made on both sides with underpowered risk stratification. The qualitative study of post-TAVI cardiac rehabilitation participation (n=11, single-center, non-randomized) surfaces a related asymmetry: prehab and CR access is a poorly measured determinant of TAVR outcomes that does not appear in any comparison with SAVR.
Device & Technology
Three technique papers read as a coherent statement about where operator attention now sits. The Radiology: Cardiothoracic Imaging redo-TAVR CT review formalizes what the ESC 2025 lifetime-management framework demands: commissural alignment, coronary access, and neo-skirt height at the index procedure determine what is possible at reintervention. The BASILICA review in European Cardiology covers the mitigation technique for coronary obstruction — a complication whose absolute numbers grow with TAV-in-TAV volume. The Future Cardiology direct-TAVI review supports selective, anatomy-driven predilatation over routine BAV for bicuspid anatomy, severe calcification, or horizontal aorta. A CABG technology described in Cardiovascular Business as a "technical breakthrough" warrants skepticism until peer-reviewed outcomes appear.
Industry & Market
Edwards Lifesciences beat Q2 estimates and narrowed its full-year sales outlook upward, with TAVR and TMTT franchises driving the beat. Venus Medtech's completed enrollment in its self-expanding TAVR pivotal — data readout will determine whether a fourth global self-expanding platform is commercially viable against Evolut and ACURATE.
Financial Analysis
Edwards' beat-and-raise quarter is best read alongside today's M-TEER mortality paper. Transcatheter valve commercial expansion is outpacing the evidence base for patient selection, and that mismatch will surface in payer scrutiny of appropriateness criteria. The 12.5–13.6% top-line growth reflects volume; the outcome literature asks about timing. If ESC 2025's Class I upgrade for early MV repair diffuses into US practice, the M-TEER growth curve compresses at the top of the funnel (earlier surgical referrals) while expanding at the bottom (secondary MR under expanded COAPT-like criteria). Net direction is unclear; competition for the same patient is definitively up. For TAVR, the Venus Medtech enrollment completion is a reminder that platform crowding is accelerating just as the guideline age-threshold divergence — ESC ≥70 TAVI-preferred versus ACC/AHA >80 — creates geographic volume asymmetries.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Price: $83.82, down $0.55 (-0.65%) on the earnings day; 6-month change essentially flat (-0.53%)
- Market cap: $48.3B | P/E trailing: 45.55 | P/E forward: 24.93 | Beta: 0.85
- 52-week range: $72.30–$96.29
- Analyst target: $99.00 (range $84–$110, 25 analysts) | Rating: Buy
- Earnings: Reported Q2 2026 today — beat on EPS and revenue, raised full-year sales guidance
- Commentary: The Q2 beat was TAVR- and TMTT-driven. The muted price reaction (down slightly despite the beat) points to guidance raise largely priced in after the initial after-hours pop. The 6-month flat performance despite fundamental strength points to sector rotation pressure rather than a company-specific problem.
Medtronic (MDT)
- Price: $82.01, up $0.12 (+0.15%); 6-month change -17.13%
- Market cap: $105.0B | P/E trailing: 21.99 | P/E forward: 12.80 | Beta: 0.58
- 52-week range: $73.31–$106.33
- Analyst target: $97.84 | Rating: Buy
- Earnings: September 1, 2026 (EPS est $1.39, Rev est $9.55B)
- Commentary: The 17% 6-month decline reflects broader concerns about the diabetes and neurovascular franchises, not Evolut. Structural heart specifically remains a bright spot.
Abbott (ABT)
- Price: $100.75, up $0.18 (+0.18%); 6-month change -6.13%
- Market cap: $175.5B | P/E trailing: 32.61 | P/E forward: 16.61 | Beta: 0.61
- Analyst target: $118.67 | Rating: Buy
- Earnings: October 14, 2026
- Commentary: TriClip momentum and the Navitor TAVR ramp remain the structural heart storylines. The ESC 2025 Class IIa endorsement of transcatheter TR treatment is a medium-term tailwind for the TriClip franchise.
Boston Scientific (BSX)
- Price: $43.58, up $0.61 (+1.42%); 6-month change -53.42%
- Market cap: $64.8B | P/E trailing: 18.01 | P/E forward: 11.74 | Beta: 0.58
- Analyst target: $72.43 | Rating: Strong Buy
- Earnings: July 29, 2026 (EPS est $0.83, Rev est $5.37B)
- Commentary: The 53% 6-month drop is dominated by non-valve issues (WATCHMAN, EP), but the ACURATE neo2 US commercial pause following the ACURATE IDE data remains a structural heart overhang. Q2 print next week will be watched for any update on the ACURATE platform.
Anteris Technologies (AVR.AX)
- Price: $11.37 AUD, down $0.43 (-3.64%); 6-month change +23.59%
- Market cap: $1.1B AUD | P/E forward: -5.21 (unprofitable) | Beta: 0.73
- Analyst target: $13.00 (1 analyst)
- Commentary: The DurAVR THV story remains speculative and enrollment-dependent. The 23% 6-month gain reflects small-cap enthusiasm rather than pivotal data.
Market outlook: Edwards' print confirms that TAVR and TMTT volume growth remain the dominant structural heart tailwinds. The 2528-patient M-TEER mortality paper released alongside those results is a reminder that appropriateness criteria — not device availability — will define the next phase of the market. Payers and guideline bodies are moving toward earlier intervention (ESC 2025 asymptomatic AS Class IIa, PMR upgrade to Class I in high-risk asymptomatics). That reshapes the funnel more than any device iteration.
Clinical Trial Updates
Aortic:
- NCT07486739 — Functional and Structural Assessment of the Heart by AI-enabled ECG for Management of Atrial Fibrillation | Status: Not yet recruiting | Phase: NA | Enrollment: 1724 | Sponsor: Seoul National University Hospital. AI-ECG for structural heart screening is adjacent to but not directly a valve trial; worth tracking for downstream AS/MR case finding.
No new updates today in dedicated valve trial categories (Mitral Repair, Mitral Replacement, Tricuspid Repair, Tricuspid Replacement). REPAIR-MR, PRIMARY, TRILUMINATE Pivotal, CLASP-TR, APOLLO, TRISCEND II, and the PARTNER family continue as landmark reference points; no status changes reported.
Social & Conference Highlights
No conference-specific social signal today. Edwards Q2 earnings call dominated cardiac Twitter/X and financial media.
Boston Scientific Q2 on July 29 will test whether the ACURATE neo2 franchise has a defined US path forward and whether TriClip's ESC-endorsed tailwind is materializing in real volume. The larger question the M-TEER registry raises — when to refer, not what to implant — will define which franchises grow on volume and which on penetration into earlier disease.